GlassScriptPhysician profile
Chandni Anand
NPI 1518908862
$2,546.31
in general payments reported to CMS, 2019-2025
25 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.33 · 2022: $47.59 · 2023: $426 · 2024: $972 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $705.11 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $310.66 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $272.93 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $250.45 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $245.84 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.94 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $89.35 | 2023-2024 | Veozah |
| Pfizer INC. | $80.40 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.20 | 2024-2025 | |
| Exact Sciences Corporation | $63.20 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $46.93 | 2019-2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $40.40 | 2024-2025 | Nexletol |
| Medtronic, INC. | $28.15 | 2025 | Venaseal |
| Phathom Pharmaceuticals, INC. | $25.52 | 2024 | Voquezna |
| Itamar Medical INC | $24.69 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.03 | 2024 | Korlym |
| Abbvie INC. | $22.98 | 2023 | Synthroid |
| Almatica Pharma LLC | $20.01 | 2023 | Loreev Xr |
| Abbott Laboratories | $19.33 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.82 | 2023 | Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.09 | 2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $16.47 | 2023 | Quviviq |
| Dexcom, INC. | $15.80 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $15.63 | 2025 | Flucelvax, Fluad |
| Intra-Sana Laboratories | $14.38 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandni Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.